2025 Tandem Meetings | Blood Cancers Today

MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.

Adding ruxolitinib before, during, and after HSCT to standard GVHD prophylaxis reduced the incidence of GVHD.

$Can Teclistamab Address Renal Impairment in Relapsed or Refractory Multiple Myeloma?$

A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.

Several hematologists were recognized for their contributions to the fields of HSCT and cellular therapy.

CAR22 therapy demonstrated an ORR of 100% and a complete response rate of 83% in six patients with MCL or FL.

$Zamto-Cel Induces Strong Responses in Relapsed or Refractory DLBCL$

Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.